Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: kas1 who wrote (248)	6/7/1998 7:36:00 AM
From: James Baker	Respond to of 642

Evista is featured on the Weekend Mag with Stone Phillips on MSNBC Saturday morning and repeated in the evening. The piece is extremely favorable describing the 50-70% reduction in breast cancer risk as well as osteoporosis and heart disease prevention. The contrast with Tamoxifan is clearly drawn with better results for Evista and none of the uterine cancer worries. It was truly as good a commercial for Evist as the company ever could write and just like Viagra - all free. Jim

To: kas1 who wrote (248)	6/7/1998 3:29:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

FDA Issues Proposal for 'Off-Label' Advertising of Products Bloomberg News June 5, 1998, 12:59 p.m. PT FDA Issues Proposal for 'Off-Label' Advertising of Products Washington, June 5 (Bloomberg) -- Companies will be able to tell doctors, insurers and government agencies about unapproved uses or benefits of drugs or medical devices already on the market, under a new U.S. Food and Drug Administration proposal. Under the new regulation, companies could distribute certain information to health professions -- such as a medical journal article -- as long as they abide by set of rules. Among other things, companies must inform the FDA ahead of time, ensure the product doesn't pose ''a significant risk'' to patients and agree to submit an application for the new claim within three years among other things, the agency said. The proposal on so-called off-label uses of products is one of several regulations the FDA is required to draft under an agency overhaul act passed by Congress last year. In the past, the FDA refused to allow companies to advertise unapproved claims about an approved product to doctors, saying that would eliminate an incentive to prove the claim with research. The FDA overhaul law ''and the new proposed rules tie dissemination of this information to a commitment to do the necessary research on the new uses,'' said William Schultz, the FDA's deputy commissioner for policy. One potential beneficiary of the new regulation would be Eli Lilly & Co. The Indianapolis-based drugmaker is studying its Evista osteoporosis prevention drug for use in preventing and treating cancer. Under the new rules, the company could distribute preliminary studies to doctors showing the drug's benefits in cancer as it prepares its application for formal FDA approval of that use. The proposal is open for comment for 45 days, the FDA said. A final rule is supposed to be in place by Nov. 21, one year after the FDA overhaul bill's enactment, the agency said. --Kristin Jensen in the Washington newsroom (202) 624-1843 /mfr